Vaxcyte, Inc.
PCVX
Kedudukan dalam Saham
#2081
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Harga Saham
$64.29
Modal Pasaran
$9.86B
Perubahan (1 hari)
1.05%
Perubahan (1 tahun)
51.66%
Negara
US
Perdagangan Vaxcyte, Inc. (PCVX)
Kategori
Healthcare
Bilangan saham terbitan bagi Vaxcyte, Inc. (PCVX)
Bilangan saham terbitan setakat June 2026: 144.49M
Menurut laporan kewangan terkini dan harga saham Vaxcyte, Inc., bilangan saham terbitan semasa ialah 144.49M. Pada akhir December 2023, syarikat mempunyai 97.16M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Vaxcyte, Inc. (PCVX) dari 2017 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 144.49M | 18.44% |
| 2024 | 122.00M | 25.57% |
| 2023 | 97.16M | 49.75% |
| 2022 | 64.88M | 24.95% |
| 2021 | 51.92M | 75.74% |
| 2020 | 29.55M | 678.52% |
| 2019 | 3.80M | 4.57% |
| 2018 | 3.63M | 1.80% |
| 2017 | 3.57M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | 75.72% |
US
|
|
| 396.00M | 174.06% |
US
|
|
| 478.91M | 231.44% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -56.96% |
NL
|
